Table 3.

Relationship between progress-free survival and Beclin 1 expression, EGFR and ALK rearrangements in lung cancer patients

Gene	Expression or mutation	Progress-free survival (month)			t	P value
		Average	Standard error	95% CI
Beclin 1	High	22.11	3.21	17.87–34.21	4.882	0.000
	Low	34.91	4.61	27.27–47.11
EGFR	Negative	18.33	5.11	12.17–24.66	7.542	0.000
	Positive	27.14	3.91	19.07–38.71
ALK	Negative	21.31	4.01	16.17–31.41	11.324	0.000
	Positive	31.21	4.11	27.57–44.26